TRVI - NASDAQ

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

TRVI·NASDAQ

$13.45

-3.6%
HealthcareBiotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.91B
EPS-0.2900
P/E Ratio-46.38
Earnings Date08/06/2026

trvi

Selling, General and Administrative Expenses

Last Annual Value

15.85M

3-Year CAGR

16%

5-Year CAGR

9%

10-Year CAGR

25%

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses

TRVI · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
TRVI logo
Trevi Therapeutics, Inc.
NASDAQ:TRVI
15.85M
15.7%10.8%25.0% 
ARDX logo
Ardelyx, Inc.
NASDAQ:ARDX
337.23M
35.9%36.1%33.5%
ZBIO logo
Zenas BioPharma, Inc.
NASDAQ:ZBIO
53.32M
46.1%N/AN/A
ORIC logo
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
33.19M
9.0%8.6%N/A
NVAX logo
Novavax, Inc.
NASDAQ:NVAX
150.35M
-31.6%-12.8%12.4%
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
70.13M
20.2%N/A-6.8%
TRML logo
Tourmaline Bio, Inc.
NASDAQ:TRML
22.75M
20.4%700.5%N/A
TERN logo
Terns Pharmaceuticals, Inc.
NASDAQ:TERN
32.23M
-6.2%10.5%N/A
UPB logo
Upstream Bio, Inc.
NASDAQ:UPB
17.17M
17.1%N/AN/A
Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. Fair Value Envelope

TRVI · NASDAQ

Our analysis suggests that TRVI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.45, this represents a potential HIDDEN relative to our calculated worth for Trevi Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $13.45

Related Guides

Blog Categories

Continue your TRVI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.